Sign in to view content

The Impact of the COVID-19 Pandemic on Aflibercept and Ranibizumab Anti-VEGF Injections

Kapil Mishra, MD

Video
Published 2021

Related

Treatment Switch From Aflibercept to Ranibizumab Pre-filled Syringe in Canadian DME Patients in a Real-World Setting: The PRECISE Study
Michel R Giunta, MD
On Demand Cases, Courses, and Papers
2021
PULSAR Extension: Clinical Improvements Sustained Over 156 Weeks With Aflibercept 8 mg in Patients With Neovascular Age-Related Macular Degeneration
David T.W. Wong, MD, FRCS(C), FASRS
Updates from the Field
2025
Number of Injections and Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER
Carl D. Regillo, MD
Annual Meeting Talks
2020

Category: Socioeconomics

See more